|
Synonyms: GNC 038 | GNC-038 | GNC038
Compound class:
Antibody
Comment: Emfizatamab (GNC-038) is a humanized immunotherapeutic monoclonal antibody that is engineered to engage 4 molecular targets (tetra-specific), to provide immunostimulatory and antineoplastic activities as an approach to treat B cell malignancies. The protein targets are CD19, CD3e, PD-L1 and 4-1BB. Emfizatamab is designed to crosslink CD19-expressing tumour B cells with cytotoxic T lymphocytes (via CD3e binding). It also targets PD-L1 on the tumour cells (preventing interaction with the inhibitory T cell checkpoint protein PD-1), and engagement of 4-1BB (TNFRSF9) acts as a co-stimulatory signal on T cells that is proposed to enhance anti-tumour activity. Likely one of the so-called 'guidance and navigation control (GNC)' proteins that are claimed in Sichuan Baili Pharmaceutical/Systimmune patent US20210024630A1 [1].
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 12023 | emfizatamab |
| Synonyms |
| GNC 038 | GNC-038 | GNC038 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1248 |
| Other databases | |
| GtoPdb PubChem SID | 472319299 |
| Search PubMed clinical trials | emfizatamab |
| Search PubMed titles | emfizatamab |
| Search PubMed titles/abstracts | emfizatamab |
